Wednesday 12 October 2016

ADVANCE NOTICE: The Fourth International Workshop on Therapeutic Tolerancing


 

Therapeutic Tolerance Workshop 27-30th June 2017

Confirmed Speakers


R Germaine, (Bethesda, USA)

Keynote address: Imaging the immune system

 

G Hollander (Oxford, UK)

The thymus – an update

 

E Shevach (Bethesda, USA)

Regulatory T cells

 

F Powrie (Oxford, UK)

Manipulating the microbiome for tolerance induction

 

D Sansom (London, UK)

What does CTLA4 really do?

 

S Khleif (Augusta, USA)

Title TBC

 

T Johnson (Augusta, USA)

Trials and tribulations in breaking tumour tolerance

 

PP Tak (Stevenage, UK)

Immunomodulation by vagal nerve stimulation

 

H Jonuleit (Mainz, Germany)

Tolerogenic targets in regulatory T cells

 

I Anegon (Nantes, France)

Novel mechanisms in tolerance induction

 

J Isaacs (Newcastle, UK)

Update on the RA-MAP consortium

 

M Hernandez-Fuentes (London, UK)

Biomarkers in transplantation tolerance

 

G Kassiotis (London, UK)

Endogenous retroviruses and the breakdown of immune tolerance

 

G Lombardi (London, UK)

Tregs in kidney transplantation

 

R Thomas (Brisbane Australia)

A platform for peptide therapeutics

 

G Schett (Erlangen, Germany)

Autoantibodies as tolerance biomarkers

 

M Trucco (Pittsburgh, USA)

Tolerogenic therapies for type I diabetes

 


L Chatenoud (Paris, France)

Anti-CD3 – an update

 

A Coles (Cambridge, UK)

Alemtuzumab in Multiple Sclerosis

 

M Ehrenstein (London, UK)

Anti-TNF as a tolerogenic therapy

 

A Mellor (Newcastle, UK)

IDO and tolerance – where are we now?

 

D Howie (Oxford, UK)

How FoxP3 regulates immune metabolism

 

L Graca (Lisbon, Portugal)

Tolerance to Factor VIII

 

H Waldmann (Oxford, UK)

Novel antibodies with improved properties?

 

J van Laar (Utrecht, The Netherlands)

Hematologic transplantation as a therapy for autoimmunity

 

A Radbruch (Berlin, Germany)

Restoring B cell tolerance

 

F van Wijk (Utrecht, The Netherlands)

Resetting T cell regulation in JIA

 

M Bernardo (Milan, Italy)

Mesenchymal for tolerance induction

 

D Wraith (Birmingham, UK)

Peptide therapy in MS and other conditions

 

L Klareskog (Stockholm, Sweden)

Evolution of an autoimmune disease

 

P Trzonkowski (Gdansk, Poland)

Treg therapies in type I diabetes

 

C Mauri (London, UK)

Regulator B Cells

 

K Kishimoto (Massachusetts , USA)

Tolerogenic nanoparticles

 

R Wilkinson (Cambridge, UK)

Title TBC

 


For further information please contact lisa.tait  @ ncl.ac.uk